Facebook Linkedin Mail Twitter Youtube
Facebook Linkedin Mail Twitter Youtube
    Latest

    Structural Heart

    ESC 2020 Congress: TMVR with Tendyne results in favourable LV remodelling

    Transcatheter tricuspid valve replacement “low risk” for complications

    First 10-year report of TAVI durability indicates a low rate of structural valve deterioration

    A higher volume of mitral valve repair procedures is associated with lower mortality rates

    PCR e-Course 2020: Bicuspid TAVI is feasible, safe and efficient

    PCR e-Course 2020: Left atrial appendage occlusion improves clinical outcomes vs NOACs in high risk AF patients

    PCR e-Course 2020: Reduction in tricuspid regurgitation with TriClip edge-to-edge repair is sustained at one year

    PCR e-Course 2020: DEFINITION II finds two-stent approach better than provisional in complex lesions

    PCR e-Course 2020: Evolut Low-Risk trial confirms TAVI is non-inferior to surgery, and establishes it is cost-effective

    First evaluation of long-term outcomes after aortic valve-in-valve presented at PCR e-Course 2020

    PCR e-Course 2020: Evoque demonstrates feasibility for mitral valve replacement via a transseptal approach

    PCR e-Course 2020: Mitral valve-in-valve and valve-in-ring strategies often require repeat procedures

    Evolut gets CE mark in low-risk patients and new labelling for bicuspid use

    Blue Sail Medical and Biosensors International acquire TAVI company NVT

    MicroPort obtains CE mark for PathBuilder

    Keith Oldroyd to become CMO at Biosensors

    Bicuspid TAVI outcomes as good as those for tricuspid

    Transcatheter tricuspid valve repair shows promise for reducing heart failure hospitalisations

    Jeffrey J Popma joins Medtronic as vice president and chief medical officer for coronary, renal denervation, and structural heart businesses

    CE mark PASCAL clip-based system for transcatheter tricuspid repair

    SCAI 2020: Strong 10-year performance for Melody transcatheter pulmonary valve

    COVID-19: Survey suggests increased operating days may be required to clear elective backlog

    American Academy of Neurology recommends PFO closure for selected stroke patients

    Boston Scientific reveals CE mark for Acurate neo 2 in Q1 financial results report

    Pi-Cardia closes a US$27 million financing round led by Sofinnova Partners

    COVID-19: “Essential” vs. “non-essential” TAVI procedures can be difficult to determine

    CE mark for transcatheter system that uses same clip technology as MitraClip

    Cancer patients should not automatically be excluded from TAVI

    Techno-College Innovation Award for LifeMatrix bioengineering platform

    COVID-19: Edwards pauses enrolment in mitral and tricuspid trials to allow hospitals to focus on virus

    Virtual ACC: Edoxaban non-inferior to warfarin for preventing thromboembolism after surgical bioprosthetic valve replacement

    MitraClip in moderate surgical risk patients

    Virtual ACC: Newer generations of MitraClip associated with greater reduction in mitral regurgitation than previous version

    BCIS and BCS ratify NHS guidance for cardiology during COVID-19 pandemic

    ageing mitral valve surgery

    Frailty predicts greater death rate and higher costs after mitral valve surgery

    Transcatheter heart valves are overlapping with coronary arteries

    TriGUARD 3 given CE mark for embolic protection during TAVI

    Early quality of life increases or benefits in COAPT translate to better long-term clinical outcomes

    Novel device “safely obliterates” left atrial appendage with minimal amount left behind

    Approval of Tendyne TMVI device means physicians now have a portfolio of options for treating mitral regurgitation

    Abbott receives CE mark for FlexNav delivery system

    CRT 2020: TAVI safe at 30 days in low-risk bicuspid aortic stenosis

    CRT 2020: Stage 3 kidney injury after TAVI leads to seven times higher mortality

    Edwards Life sciences initiative

    Edwards expands its Every Heartbeat Matters initiative

    Self-expanding and balloon-expandable valves are equally effective in high-risk TAVI

    Cardiovalve

    Cardiovalve receives Breakthrough Device Designation for its transcatheter tricuspid valve replacement system

    “Our goal is to treat more patients with mitral regurgitation”

    Germany renews Revivent’s NUB reimbursement status 1 for 2020

    Abbott becomes first company in world to have transcatheter mitral implantation device on market

    Low albumin, anaemia, and slow walking speed predict mortality after TAVI

    SAFEPASS 2 clinical study of the Emboliner embolic protection catheter

    Emboline completes enrolment in SAFEPASS 2 clinical trial

    BIBA Briefings: Sapien 3 becomes first TAVI valve to be approved for low-risk patients in both Europe and the USA

    Routine anticoagulation with rivaroxaban after TAVI harmful: GALILEO trial results

    BIBA Briefings: Longest and largest follow-up data for Watchman supports its role in stroke prevention

    AHA 2019: ISCHEMIA shows no benefit for revascularisation in patients with stable ischaemic heart disease

    PCR London Valves 2019: Meril unveils positive data for Myval

    PCR London Valves 2019: PARTNER 2 analysis shows Sapien 3 valve as durable as surgical valves at four years

    PCR London Valves 2019: TRILUMINATE shows safety and efficacy of TriClip maintained at one year

    PCR London Valves 2019: A simple algorithm can reduce unnecessary pacemaker implantation after TAVI

    PCR London Valves 2019: One-year survival better with Mitra Clip than with medical therapy among COAPT-excluded patients

    ADVERTORIAL: Answering the question of durability is TAVI’s next challenge

    Multiphase and early systolic phase CT screening in TMVR superior to end systole analysis at predicting obstruction risk

    Left atrial appendage closure associated with a decreased stroke risk in AF patients

    Pre-TAVI aortic regurgitation aids survival post-TAVI in mixed aortic valve disease patients

    ADVERTORIAL: Edwards PASCAL™ Transcatheter Valve Repair System is associated with a “striking” reduction in mitral regurgitation

    Admedus sells CardioCel and VacsuCel to focus on TAVI

    AccuCinch ventricular repair system associated with favourable safety profile at 30 days

    Transseptal puncture techniques must be mastered if physicians wish to perform left-sided interventions

    TCT 2019: TAVI has sustained health status benefits over surgery for low-risk patients at one year, with similar five-year outcomes for intermediate-risk patients, unless via a transthoracic route

    TCT 2019: COAPT finds MitraClip safety and efficacy is maintained at three years, and is cost-effective

    FDA approves Evolut PRO+

    AtriCure agrees to buy LARIAT developer SentreHEART

    ADVERTORIAL: Device and procedural innovations have led to improved efficiency with TAVI

    Novel repositionable TAVI valve has acceptable early clinical outcomes

    ESC 2019: Two-year findings of MITRA-FR continue to show no prognosis benefit with MitraClip

    ESC 2019: Left atrial appendage closure is non-inferior to NOACS for preventing major neurological, cardiovascular, and bleeding events

    FDA approves Sapien 3 Ultra, Sapien 3, and CoreValve for low-risk TAVI

    Edwards Lifesciences drops Centera in favour of focusing on Sapien range

    Myval: India’s TAVI technology is now going global

    Age alone should not preclude TAVI in patients aged ≥90 years

    The findings on transcatheter aortic valve implantation in patients who are at low risk for cardiac surgery will usher in a new era for patients

    Edwards Lifesciences to discontinue its self-expanding valve Centera

    Edwards Lifesciences issues urgent safety notice for Sapien 3 Ultra

    Carillon Mitral Contour System reaches 1,000 implants for functional mitral regurgitation

    Medtronic announces global registry of HVAD thoracotomy implants

    FEops HEARTguide wins CSI Highlight of the Year Award

    Edwards Lifesciences issues an urgent field safety notice for Centera TAVI system

    Admedus’ announces favourable five-year outcomes for its CardioCel bioscaffold

    Patent granted to Valfix Medical for its percutaneous valve and replacement technology

    India-designed Myval associated with no device-related mortality at one year

    DSM and SAT enter partnership to develop the first next-generation heart valve

    CMS’ update to coverage policy for TAVI provides greater flexibility for hospitals and providers

    New trial to compare Watchman FLX to direct oral anticoagulants

    TVT 2019: PASCAL system may be beneficial for managing tricuspid regurgitation

    TVT 2019: Purpose-designed temporary pacing guidewire has potential to make implantation of transcatheter heart valves “safer and more efficient”

    TVT 2019: TAVI is “preferred therapy” for low-risk patients

    A “crackdown” on alternative access for TAVI

    NeoChord raises additional financing to drive catheter‐based programme development

    Lotus Edge becomes third TAVI device on US market

    TAVI company Tioga Medical closes US$15M in series A financing

    CE mark for the FEops HEARTguide

    Reconciling the contrasting findings on MitraClip, and implications for the management of functional mitral regurgitation

    ACC 2019: TAVI moves to the mainstream with new findings in low-risk patients

    CRT 2019: Evolut R superior to surgery at one year in intermediate-risk patients

    MitraClip in moderate surgical risk patients

    MitraClip can be used to treat secondary mitral regurgitation in the USA

    Micro Interventional Devices enters strategic alliance with Oscor

    ACC to offer transcatheter valve certification to help hospitals implement best practices

    Innovative cardiovascular systems announce first use of its next-generation Emblok embolic protection system in European feasibility study

    Sapien 3 provides safe and satisfactory access via the transcarotid route

    ADVERTORIAL: The Edwards Cardioband™ Tricuspid Valve Reconstruction System is associated with considerable improvement in functional outcomes

    CE mark for PASCAL mitral valve repair system

    Long-term function of TAVI valves “is excellent”

    The Tricento transcatheter heart valve: A novel approach for the treatment of tricuspid regurgitation

    US FDA grant premarket approval to Manta vascular closure device

    ADVERTORIAL: “We are now at a new era of TAVI where we have very high rates of device success”

    TAVI-induced bundle branch block and permanent pacemaker implantation are “not benign”

    First United States treatment with J-Valve TAVI device

    Sapien 3

    Sapien 3 Ultra receives FDA approval

    BioCardia submits 510(k) application to US FDA for its Avance steerable introducer for transseptal access to heart

    US District Court for the District of Delaware rules that Sapien 3 infringes a Boston Scientific patent

    Abiomed invests $15 million in Shockwave Medical

    Edwards Lifesciences to collaborate with Bay Labs to use AI software to improve detection of heart disease

    MitraClip in moderate surgical risk patients

    Draft NICE guidance supports use of percutaneous mitral valve repair

    First implant of Pascal transcatheter mitral valve repair device performed in CLASP IID trial

    TAVI-proof procedures and device designs

    JenaValve receives FDA approval for expanded IDE enrolment in the treatment of patients with severe aortic stenosis and severe aortic regurgitation

    Presence of left bundle branch block significantly increases risk of pacemaker implantation after TAVI

    BASILICA: A new approach for preventing coronary obstruction in TAVI

    US FDA plan shakeup of its 510(k) clearance programme

    Sapien 3

    Launch of Sapien 3 Ultra hampered by Boston Scientific dispute

    Vivasure Medical announces launch of the PerQseal large bore closure device

    NeoChord announces US$25 Million Series D financing to accelerate development of two transcatheter chordal repair programmes

    TCT 2018: Sham-controlled trial indicates indirect annuloplasty reduces mitral regurgitation

    Cordis launches Mynx Control vascular closure device in the USA

    First US implantations of TriCinch Coil tricuspid valve repair system performed

    Atrial fibrillation related to PFO closure occurs early and is transient

    TCT 2018: Durable tricuspid regurgitation reduction with MitraClip

    TCT 2018: Severe prosthesis-patient mismatch linked to increased mortality at one year

    iVascular acquires 10% of NaviGate Cardiac Structures for US$10 million

    First patient enrolled in STTAR study of MIA—minimally invasive annuloplasty

    TMVI with Tiara valve may be safe and feasible for patients with prior aortic valve replacement

    FDA approve TSP Crosser transseptal access system

    Teleflex buys vascular closure company Essential Medical

    ADVERTORIAL: Tricuspid annular reduction using Edwards Cardioband (TM) Tricuspid Valve Reconstruction System in a patient with severe tricuspid regurgitation and large coaptation gap

    US trial of Edwards’ self-expanding Centera valve begins

    ADVERTORIAL: Unique design and features of the ACURATE neo (TM) enable safe and efficient procedures

    Olaf Wendler

    Venus Medtech to buy cerebral protection device company Keystone Heart

    TCT 2018: One-year real-world results show Portico TAVI system reduces severe aortic stenosis

    TCT 2018: Longest-term data to date for CoreValve study show excellent valve durability out to five years

    TCT 2018: Audience claps as COAPT shows MitraClip reduces HF hospitalisations

    US FDA approve study of CoreValve Evolut in low-risk patients with bicuspid valves

    First patient enrolled in CARILLON pivotal trial

    PCR LV 2018: One-year results of VIVA confirm safety and efficacy of valve-in-valve procedures with CoreValve

    PCR LV 2018: Early discharge feasible for unselected TAVI patients

    PCR LV 2018: Favourable outcomes for next-generation Acurate neo2 TAVI system

    Two patients have been implanted with latest-generation of integrated ICE delivery system

    Gore buys transcatheter mitral chordal repair technology

    ESC 2018: TMVI associated with “excellent outcomes” for valve-in-valve procedures

    Patients with new-onset atrial fibrillation after TAVI have highest risk of complications

    ESC 2018: First US FDA-approved study shows TAVI is safe for low-risk patients

    ESC 2018: MitraClip makes “absolutely no difference” for the prognosis of secondary mitral valve regurgitation

    Revising the National Coverage Determination for TAVI: The real barrier to care is not volume requirements

    Simultaneous TAVI and left atrial appendage closure is feasible

    ADVERTORIAL: Edwards’ CardiobandTM Tricuspid Valve Reconstruction System: A new option for under-treated patients

    Novel Ultraseal device is a feasible option for left atrial appendage closure

    Three-quarters of patients have sustained results at very long-term follow-up after percutaneous balloon mitral valve valvuloplasty

    Chronic kidney disease should not be a barrier to TAVI

    “Tricuspidisation” could be a potential approach to performing TAVI in certain patients with bicuspid valves

    Patient enrolment in US early feasibility study of Everdur TAVI device initiated

    PRECLUDE study of Caisson TMVI system concludes

    Boston Scientific closes acquisition of Claret Medical

    On the fence result for initial CMS vote about TAVI volume requirements

    Abbott launches trial of its Tendyne transcatheter mitral valve implantation device

    Boston Scientific to buy cerebral protection system company

    US FDA clearance for TEECAD system for aiding transoesophageal echocardiography

    Leaflex Performer: A non-implant based treatment for aortic stenosis

    MitraClip in moderate surgical risk patients

    Next-generation of MitraClip approved for use in the USA

    Consider the transaortic approach when faced with difficult iliofemoral anatomy

    Malnourished patients have a three-fold risk of mortality after aortic valve replacement

    ADVERTORIAL: Edwards Cardioband™ Mitral Valve Reconstruction System—Reliably addressing annular dilatation

    TVT 2018: New-generation TAVI devices perform well in patients with large annuli

    Leaflet thrombosis is not a predictor of stroke or all-cause mortality in the medium term

    TVT 2018: Tiara TMVI device featured in live case

    Carotid disease is not a risk factor for stroke or death in TAVI patients

    ADVERTORIAL: ACURATE neo: A “very safe” TAVI system providing “extremely good results in almost all patients”

    TVT 2018: Positive results for Manta large bore closure device

    Implantation of JenaValve successful in initial patients enrolled in CE mark study

    First patient enrolled in phase II of REFLECT study of TriGuard 3

    Combination of high-sensitive C-reactive protein with logistic EuroSCORE improves risk stratification in TAVI patients

    EuroPCR 2018: Low incidence of cardiovascular mortality with Centera self-expanding valve at one year

    EuroPCR 2018: No significant difference in bioprosthetic valve dysfunction between surgical and TAVI devices at six years

    EuroPCR 2018: Real-world data confirm trial outcomes for Sapien 3

    ADVERTORIAL: Sentinel Cerebral Protection System provides reassurance to both physicians and patients

    “Excellent valvular function” with NaviGate’s GATE tricuspid valved stent at one year

    Enrolment of US early feasibility study of AccuCinch system for left ventricular repair expanded

    EuroPCR 2018: Boston Scientific outlines its key presentations

    First patient treated in first-in-man study of ChordArt mitral valve repair system

    EuroPCR 2018: First-in-human study of Leaflex Performer for aortic stenosis initiated

    CoreValve shows “favourable performance” at long-term follow-up

    Cardiac Dimensions appoints Matthew Stark as vice president of Clinical and Regulatory Affairs

    Cardioband becomes first-ever transcatheter tricuspid system to receive the CE mark

    SCAI 2018: 3D model could be used to predict paravalvular leak after TAVI

    Ticagrelor may be an effective tool for suppressing platelet reactivity after TAVI

    TMVI in inoperable patients is feasible but mortality high at one year

    TAVI is increasingly seen as the preferred approach for aortic valve replacement in CABG patients

    Boston Scientific successfully opposes Edwards Lifesciences Corporation’s European patent EP 2,399,550 (550)

    CE mark for HeartStitch’s transapical access and closure device

    Location of tricuspid regurgitation predicts procedural success of percutaneous edge-to-edge repair

    US FDA approves Cardioform septal occluder for PFO closure to prevent recurrent ischaemic stroke

    Study of next-generation JenaValve device completes enrolment

    Enrolment complete in CT imaging substudy of leaflet mobility with Sapien 3 in low-risk patients

    First two patients enrolled in early feasibility study of second-generation Colibri valve

    UK Court of Appeal dismisses Edwards Lifesciences’ appeal against Sapien 3 infringement ruling

    Determining valve durability in the era of TAVI

    ACC 2018: Morphologic characteristics may determine benefit of percutaneous PFO closure

    ADVERTORIAL: “All patients” should receive cerebral protection when undergoing TAVI procedures

    ACC 2018: Five-year data for CoreValve show strong haemodynamic performance

    FDA approves the world’s smallest mechanical heart valve

    “Favourable” in-hospital outcomes for younger patients undergoing TAVI

    Edwards’ self-expanding Centera TAVI valve now on European market

    Short-term DAPT is feasible for patients undergoing percutaneous LAA closure

    Fifty US centres are now using Claret Medical’s Sentinel cerebral protection system

    Depression significantly increases mortality after aortic valve replacement

    Boston Scientific enters into an acquisition option agreement with Millipede

    Next-day discharge appears safe for TAVI patients without in-hospital complications

    Sixty-day follow-up for the MANTA US pivotal trial completed

    Team-centred approach is best way of determining need for PFO closure

    Modifying procedural technique during TAVI may lower radiation exposure to patients

    Edwards Lifesciences acquires Harpoon Medical

    Harpoon Medical acquired by Edwards

    ICI 2017: Novel transcatheter mitral valve wins Best Technology Parade Presentation

    China’s first human implantation of a retrievable TAVI device successfully completed

    Boston Scientific pushes back plans for commercialisation of Lotus Edge TAVI device

    TCT 2017: TMVI in mitral ring is a reasonable alternative for high-risk patients

    TCT 2017: Vivek Reddy on the final outcomes of PREVAIL and PROTECT-AF

    Francesco Maisano

    AHA 2017: Novel transcatheter therapy for heart failure shows promise in sham-controlled trial

    MitraClip becomes first approved device for transcatheter mitral valve repair in Japan

    TCT 2017: Two studies support feasibility of transcatheter mitral valve implantation

    Sapien 3

    TCT 2017: TAVI “should be the preferred strategy” for patients at intermediate-risk

    TCT 2017: New data for CoreValve Evolut further support its use in intermediate-risk patients  

    TCT 2017: AI-driven cardiac ultrasound company to give two presentations

    Heart valve replacement surgery may not be a morning procedure

    Controlling blood pressure may help to prevent mitral regurgitation

    TCT 2017: Boston Scientific reveals presentations at conference

    Claret Medical closes on series C financing of US$14.5m

    First patient implanted with Intrepid TMVI device in APOLLO trial

    Second successful implant of minimally invasive annuloplasty system announced

    Coronary angiography after TAVI with a self-expanding valve is challenging but feasible

    Relatively few chronic kidney disease patients require dialysis after TAVI

    PCRLV 2017: New ESC guidelines for valvular heart disease represent a new era in TAVI

    First patient enrolled in Frontier IV clinical trial of PerQseal large arteriotomy closure technology

    TCT 2017: Alec Vahanian to receive the Master Clinical Operator award

    Data for NobleStitch EL suture based closure system presented at CSI UCSF Congress

    No significant differences in post TAVI outcomes between African Americans and Caucasians

    Essential Medical completes enrolment in US IDE trial of Manta

    Enrolment completed in US pivotal clinical study of Cardioform ASD Occluder

    PCR LV 2017: Refining implantation technique and device iterations may improve pacemaker rate seen with Lotus

    Bioresorbable valves: Insights into a potential game-changing technology

    Philippe Généreux appointed chief medical officer of Saranas

    FORWARD PRO clinical study to evaluate longer term performance of CoreValve Evolut Pro

    Three studies support efficacy of PFO closure for reducing risk of recurrent stroke

    Toddler

    Re-interventions common in long-term Fontan procedure survivors

    PCR LV 2017: The optimal modalities for imaging for mitral and tricuspid valve interventions

    Carag completes CE marking for its breakthrough Carag bioresorbable septal occluder

    All-comers data indicate stroke-free survival is improved with Sentinel embolic protection device

    Edwards Lifesciences’ Alterra adaptive prestent device used for first time to treat a malformed pulmonary valve

    Neovasc provides Tiara clinical update

    New literature review highlights that Perceval sutureless aortic valve is safe

    ESC 2017: Post-TAVI clinical leaflet thrombosis is “infrequently reported” but is a serious adverse event

    Minimally invasive annuloplasty has been used to successfully perform bicuspidisation of a tricuspid valve

    ProtEmbo cerebral protection system used for first time

    American societies come together to publish appropriate use criteria for valvular heart disease

    A 52mm tricuspid valve successfully implanted into a transplanted heart

    US trial to evaluate safety and efficacy of Amplatzer for patent ductus arteriosus

    Novel mitral regurgitation therapy featured in Innovation Summit at Cardiovascular Innovations

    Medtronic’s Avalus pericardial valve receives CE mark and FDA approval

    SHS invests in heart valve-repair start-up CoreMedic

    Keystone Heart accelerate trials for third-generation of its TriGuard device

    CE mark for CoreValve Evolut Pro

    4C Medical receives over US$8 million financing for transcatheter mitral regurgitation treatment

    EuroPCR 2017: A “golden era” for valve disease therapies

    Embolic protection device company raises US$5million in series B financing for advanced device development and initiation of US clinical activities

    CoreValve Evolut can be used to treat intermediate-risk patients in the USA

    Essential Frailty Toolset may be best assessment of frailty for aortic stenosis patients

    Unique 3D-printed heart valves could reduce TAVI paravalvular leakage rates

    CSI 2017: Global postmarket surveillance study to explore use of LAmbre LAA closure system

    Nearly one in 10 US TAVI procedures is off label but results seem acceptable

    First European patient enrolled in study of percutaneous tricuspid repair system

    EuroPCR 2017: Study provides “first step” towards showing long-term durability of TAVI devices

    EuroPCR 2017: No risk factor identified for early stroke events in SURTAVI trial

    Study confirms that volume matters for achieving lower in-hospital mortality after TAVI

    Bicuspid aortic stenosis: TAVI’s next challenge

    EuroPCR 2017: Greater risks with standard approach of dual antiplatelet therapy after TAVI

    German court awards Edwards Lifesciences co-entitlement of Neovasc’s Tiara patent application

    TVT 2017: Presentation showcases safety of Tempo temporary pacing lead

    Non-invasive approach could be used to improve valve opening functioning of biosprosthetic valves

    Venus Medtech buys InterValve

    US centres of TAVI excellence start to use newly approved Sentinel device

    HLT’s TAVI system implanted in first US patients

    TVT 2017: “I predict a very exciting and bright future” for transcatheter valve therapies

    Sapien 3 receives expanded FDA indication for valve-in-valve procedures

    Sentinel becomes first cerebral protection device to receive FDA approval

    Statins associated with improved heart structure and function

    Diesel pollution linked to structural and functional heart damage

    EuroPCR 2017: Excellent early outcomes for Edwards Lifesciences’ self-expanding valve

    Positive results for Gore’s PFO closure device

    EuroPCR 2017: Lotus TAVI device has superior efficacy to CoreValve at one year

    Boston Scientific closes Symetis acquisition

    EuroPCR 2017: Excellent clinical outcomes for Medtronic’s CoreValve and Evolut systems in routine practice

    NaviGate Cardiac Structures reports first heterotopic transcatheter Gate tricuspid valved stent successful implantation

    The role of nurses in ensuring a patient-focused TAVI service

    Reduced baseline left ventricular function may explain female survival benefit after TAVI

    LivaNova acquires Caisson Interventional

    Daiichi Sankyo initiates ENVISAGE-TAVI AF study to investigate once-daily edoxaban in atrial fibrillation undergoing TAVI

    New data reaffirms value of Perceval for aortic valve replacement in aortic stenosis patients

    Meta-analysis supports transaortic approach in TAVI

    Microport TARGET AC three-month sub-study results to be presented at EuroPCR

    Occlutech obtains CE mark for its Perimembranous ventricular septal defect occluder

    First patients enrolled in HLT’s Meridian transcatheter aortic valve feasibility study

    CE mark granted to NVT for Allegra transcatheter aortic valve

    TAVI pacemaker issue is “an engineering problem that will be solved”

    ACC 2017: FDA approves launch of CoreValve Evolut Pro

    ACC 2017: TAVI Linked with bleeding in the brain and neurological impairment

    TAVI may benefit certain heart valve patients, update society guidelines say

    ACC 2017: No significant differences in two-year morality between bicuspid and tricuspid aortic stenosis patients undergoing TAVI

    ACC 2017: CoreValve non-inferior to surgery in intermediate-risk patients

    Innovative Cardiovascular Solutions announces successful first use of its Emblok embolic protection system

    Early hospital discharge after TAVI less likely in women

    Melody pulmonary heart valve receives FDA approval for valve-in-valve use

    Second successful annuloplasty performed using Micro Interventional Devices minimally invasive technology

    Valve replacement may better than vavluloplasty for aortic stenosis patients with end-stage renal disease

    FDA advisory panel recommend de novo approval of Sentinel cerebral protection system

    Locking mechanism problems prompt Boston Scientific to recall all ranges of its Louts TAVI device

    Symetis acquires Middle Peak Medical

    New guidelines released to improve stroke reporting following cardiac procedures

    Understanding and managing functional tricuspid regurgitation

    Meta-analysis indicates embolic protection does reduce stroke after TAVI

    Left atrial appendage thrombus may increase the risk of stroke after TAVI

    Medtronic receives CE mark for 34mm size CoreValve Evolut R

    TAVI company Direct Flow Medical closes after failing to secure funding

    Combining MitraClip mitral valve repair with left atrial appendage occlusion is safe and feasible

    Boston Scientific may have resolved issue with Lotus Edge device

    The management of leaflet thickening after TAVI remains controversial

    New AHA/ACC guidance released for TAVI

    MicroPort completes patient enrolment of VitaFlow pre-market clinical trial

    Transcatheter valve-in-ring implantation is feasible for reducing tricuspid regurgitation

    Perform PCI prior to TAVI in patients with both coronary artery disease and aortic stenosis

    Patient with tricuspid regurgitation successfully treated with world’s first transcatheter tricuspid valved stent

    Women fare better than men one year after transcatheter aortic valve implantation

    Micro Interventional Devices has first-in-human success with MIA technology

    Minimally invasive TAVI has “several potential benefits”

    Boston Scientific closes acquisition of certain Neovasc assets

    4Tech appoints Michael Ennen as president and chief executive officer

    Boston Scientific to acquire Neovasc biological tissue capabilities

    FDA grant Cardiac Dimensions investigational device exemption approval to conduct study

    Amsel Medical to present Occluder research at ICI 2016

    Edward Lifesciences to acquire Valtech

    Neovasc receives approval to launch European study of Tiara transcatheter mitral valve

    Complete sanitation of robotic surgical instruments virtually impossible

    Trialign system successfully used to treat patient with tricuspid regurgitation because of a cardiac implantable electronic device lead

    Cardiovascular Research Foundation to launch structural heart disease journal

    TCT 2016: Patent foramen ovale closure is more effective than medical management in preventing recurrent stroke

    Pacemaker after TAVI is associated with worse outcomes

    TCT 2016: Positive data for transcatheter tricuspid repair with Trialign

    TCT 2016: Transfemoral TAVI improves quality of life in intermediate-risk patients

    TCT 2016: Tiara TMVI device highlighted in presentations

    TCT 2016: CoreValve Evolut R continues to be associated with good outcomes at one year

    NICE should develop heart valve guidelines says Heart Valve Voice

    Charity believes NHS programme will leave hundreds of atrial fibrillation patients at risk of stroke

    TCT 2016: High implant success rates with St Jude Medical’s Amulet LAA occluder

    TCT 2016: SENTINEL trial fails to meet overall primary efficacy endpoint but does in adjusted model

    TCT 2016: Positive real-world data for CoreValve Evolut R presented

    TCT 2016: FDA approve Amplatzer PFO occluder device ahead of first report investigation presentation

    TCT 2016: Valtech to host symposium about mitral and tricuspid valve repair

    TCT 2016: 30-day patient data from SCOUT I study to be presented

    FDA clear temporary pacing lead for use during TAVI and other cardiovascular applications

    FDA approval of 34mm CoreValve Evolut R means device is largest available TAVI valve in USA

    TAVI is “technically feasible” for managing aortic regurgitation in high-risk patients

    TCT 2016: Boston Scientific announces scheduled presentations

    TAVI at the end of life: Knowing when it is futile

    Health Canada grants licence to Medtronic for its CoreValve Evolut R system

    Simplified TAVI device may benefit patients with rheumatic heart disease

    Novel tricuspid therapy wins the 2016 EACTS Techno College Innovation Award

    New brain lesions are found in 94% of patients following TAVI

    Heart team at Zurich University Hospital use Cardioband for tricuspid repair for the first time

    PCRLV 2016: MitraClip may be “safe and feasible” for treating tricuspid regurgitation

    PCRLV 2016: New approaches to TAVI are still being explored

    TriGuard cerebral protection associated with significant improvements in brain protection in TAVI patients

    Claret Medical submits application for FDA approval of its cerebral protection device

    Sapien 3

    Sapien 3 now approved for intermediate-risk patients in Europe as well as in the USA

    Transcatheter tricuspid valve repair performed at San Raffaele Hospital

    PCRLV 2016: Next-generation of Lotus TAVI receives CE mark

    Valtech to present first-in-human percutaneous tricuspid repair data at PCR London Valves

    First-in-human implants of Caisson Interventional’s percutaneous mitral valve device performed

    TCT 2016: Pivotal trial on cerebral protection device to be presented as a late-breaker

    Redo TAVI procedures are safe and feasible

    “Keep it fast and simple” to avoid periprocedural stroke after TAVI

    No significant differences between Watchman and Amplatzer in first comparison

    Vivasure Medical secures €16.2 million series C financing

    St Jude Medical launches trial of Amplatzer Amulet left atrial appendage occluder

    Rose Medical Center among first hospitals in Colorado to offer Watchman

    CMS recognises LAAO Registry as approved registry to meet national coverage determination requirements

    Edwards Sapien 3 granted expanded indication from US FDA

    Boston Scientific issues urgent recall of Lotus systems manufactured prior to March 2016.

    TMVI: What we know

    Medtronic CoreValve Evolut becomes first TAVI to receive CE mark for intermediate risk aortic stenosis patients

    FDA approval for Permaseal transapical access and closure device

    The American Academy of Neurology says no to routine PFO closure for secondary stroke prevention

    Study indicates signal for valve degeneration in TAVI patients by eight years

    Safety and efficacy of Carillon mitral contour system confirmed

    Moderate risk of upper gastrointestinal bleeding after TAVI

    Manta large bore vascular closure device now approved in Europe

    Enrolment completed in US early feasibility study on tricuspid repair

    “Strikingly higher” survival rates with Sapien 3 at one year compared with older devices

    Essential Medical to begin US clinical trial of its large bore vascular closure device

    First patient treated in NOTION-2 trial of TAVI in younger patients

    Success of TAVI prompts surge in mitral valve technologies

    Cardiac & Vascular Institute becomes first North Central Florida cardiologist group to offer Watchman LAAC implant

    Percutaneous direct annuloplasty is “safe and feasible” for functional mitral regurgitation

    First patient enrolled in Keystone Heart Triguard study

    Valcare completes first phase of first-in-human Amend trial

    Transcatheter tricuspid valve repair successfully achieved in feasibility study of 4Tech TriCinch

    Investigational trial into Medtronic CoreValve Evolut R 34mm enrols first patient

    NYU Langone becomes first centre in world to use Evolut PRO TAVI system

    Permaseal transapical access and closure device now approved in Europe

    Lack of an on-site cardiac surgery department should not be a barrier to TAVI

    CE mark granted to Occlutech left atrial appendage occluder

    TAVI with Sapien 3 may be better than surgery for intermediate-risk patients

    Direct Flow Medical reports DISCOVER trial three-year results

    Jury favours CardiAQ in dispute with Neovasc

    Mitralign raises almost US$40 million in equity financing

    Pooled trial results show positive outcomes for Keystone Heart’s TriGuard

    Study suggests major clinical benefit for left atrial appendage occlusion

    Post-market study show “excellent” outcomes for Lotus TAVI valve

    Three-month data for Watchman show high success rate

    Sapien 3 demonstrates positive patient outcomes at 30 days in European real-world experience

    Moderate sedation during TAVI associated with significantly better outcomes

    Transcatheter technologies sells its technology portfolio to Venus MedTech

    Boston Scientific is suspending sales of Watchman FLX in Europe

    4Tech appoints Paul Cornelison as Global Vice President of Regulatory Affairs, Quality Assurance & Clinical Affairs

    Positive early feasibility data for pulmonary valve restoration with transcatheter pulmonary valve

    CoreValve still better than surgery at three years in high-risk patients

    FDA gives Neovasc go-ahead to add 40mm valve size to its TIARA-I clinical trial

    First patients enrolled in Medtronic CoreValve Evolut R trial in low-risk aortic stenosis patients

    Direct Flow Medical launches next generation TAVI delivery system

    Implantation height affects rate of pacemaker implantation with Sapien 3

    Sapien 3 now approved for use in Japan

    Abbott Vascular recalls MitraClip clip delivery system

    Stenting of narrow pulmonary artery benefits patients with congenital heart disease

    Study suggests no advantages with surgical approach for transfemoral TAVI

    First patients enrolled in CoreVavle Evolut R real-world study

    Edwards Sapien XT valve granted expanded FDA approval for pulmonic procedures

    Abbott issues voluntary safety notice on MitraClip delivery system deployment process

    Long-term results “will prove in favour” of specific device for closing paravalvular leak

    First J-Valve TAVI system implanted outside of China

    Carillon mitral contour system associated with significant improvement of functional mitral regurgitation

    Mitralign percutaneous annuloplasty system granted CE mark for functional mitral regurgitation treatment

    Medtronic can now investigate CoreValve Evolut R in low-risk patients

    Direct Medical Flow announce transcatheter mitral valve development program

    Valtech Cardioband reconstruction system for mitral valve repair receives reimbursement in Germany

    Non-transfemoral access is strongly associated with post-TAVI delirium

    Edwards can expand Sapien 3 study indications following FDA approval

    Gregory D Casciaro becomes president and chief executive officer of Cardiac Dimensions

    Edward Lifesciences announces further investments into mitral valve therapies

    US cardiovascular societies publish joint expert consensus on left atrial appendage occlusion requirements

    First patient enrolled in Mitralign’s US percutaneous tricuspid repair study

    MedStar Heart and Vascular Institute at MedStar Washington Hospital Center to start TAVI trial in low-risk patients

    New delivery sheath may enable more patients to undergo transfemoral TAVI

    First patient undergoes mitral replacement with NaviGate Cardiac Structures’ mitral valve stent

    Biosense Webster acquires Coherex Medical

    Next-generation Watchman approved for use in Europe

    Anticoagulation with heparin “should remain standard of care” during TAVI procedures

    SentreHeart to present data on Lariat treatment for atrial fibrillation at LAA Conference

    New transcatheter heart valve manufacturing facility certified for JenaValve

    Low baseline albumin associated with increased all-cause mortality after TAVI

    Direct Flow Medical appoints new co-principal investigator for US SALUS pivotal trial

    Further evidence needed for clinical consequences of reduced leaflet motion

    Load more

    Most read

    Bruno Scheller

    Rafael Sádaba

    Rasha Al-Lamee

    Cardiovascular News

    Write to us
    Editorial: Will Date [email protected]
    Advertising: Abbie Richardson [email protected]


    United Kingdom:

    BIBA Medical, Europe
    526 Fulham Road, Fulham, London, SW6 5NR
    TEL: +44 (0)20 7736 8788
    Email: [email protected]

    United States:

    BIBA Medical, North America
    155 North Wacker Drive, Suite 4250, Chicago, IL 60606
    TEL: +1 949 723 9309
    Email: [email protected]

    Terms and Conditions | Privacy Policy

    Facebook Linkedin Mail Twitter Youtube